EP0057 in Combination With Olaparib in Advanced Ovarian Cancer
Status:
Recruiting
Trial end date:
2025-01-01
Target enrollment:
Participant gender:
Summary
EP0057-201 is a Phase 2A/B adaptive design study. Phase 2A will test EP0057 in combination
with Olaparib and Phase 2B, the randomised part of the study, will test EP0057 in combination
with Olaparib against SOC chemotherapy. When EP0057 is combined with Olaparib, it is
envisaged that the combination should improve therapeutic responses in the recurrent ovarian
cancer disease setting.
EP0057 is an investigational nanoparticle-drug conjugate administered intravenously. The
rationale for developing EP0057 is to enable selective entry of EP0057 into tumour tissue and
as a result create preferential accumulation of EP0057, and therefore of the payload
Camptothecin, to translate into maximum tumour cell killing.